Literature DB >> 22111678

Imaging genetics: implications for research on variable antidepressant drug response.

Ulrich Rabl1, Christian Scharinger, Markus Müller, Lukas Pezawas.   

Abstract

Genetic variation of SLC6A4, HTR1A, MAOA, COMT and BDNF has been associated with depression, variable antidepressant drug responses as well as impacts on brain regions of emotion processing that are modulated by antidepressants. Pharmacogenetic studies are using psychometric outcome measures of drug response and are hampered by small effect sizes that might be overcome by the use of intermediate endophenotypes of drug response, which are suggested by imaging studies. Such an approach will not only tighten the relationship between genes and drug response, but also yield new insights into the neurobiology of depression and individual drug responses. This article provides a comprehensive overview of pharmacogenetic, imaging genetics and drug response studies, utilizing imaging techniques within the context of antidepressive drug therapy.

Entities:  

Year:  2010        PMID: 22111678     DOI: 10.1586/ecp.10.35

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  4 in total

Review 1.  Is there a personalized medicine for mood disorders?

Authors:  Lucie Bartova; Andreas Berger; Lukas Pezawas
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-19       Impact factor: 5.270

Review 2.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 3.  Use of magnetic resonance imaging in pharmacogenomics.

Authors:  Roberto Viviani; Marie-Louise Lehmann; Julia C Stingl
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

4.  A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities.

Authors:  Johanna Michl; Christian Scharinger; Miriam Zauner; Siegfried Kasper; Michael Freissmuth; Harald H Sitte; Gerhard F Ecker; Lukas Pezawas
Journal:  Eur Neuropsychopharmacol       Date:  2014-07-03       Impact factor: 4.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.